CompletedPhase 1

Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

United States41 participantsStarted 2020-05-07

Plain-language summary

This study will test the safety of Quad Shot radiation therapy using 2 different treatment schedules to find out what effects, if any, this treatment has on people with advanced NSCLC who are receiving systemic therapy for their cancer. The Quad Shot treatment schedule reduces the number of days needed to deliver the radiation treatments, which may be less disruptive to systemic therapy schedules.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically confirmed non-small cell lung cancer with metastatic disease detected on cross-sectional imaging with a plan for one of the following systemic therapies: * Carboplatin/paclitaxel * Carboplatin/paclitaxel/pembrolizumab * Carboplatin/pemetrexed * Carboplatin/pemetrexed/pembrolizumab * Pembrolizumab (single agent or in combination with other regimens in this list) * Cisplatin/pemetrexed * Cisplatin/pemetrexed/pembrolizumab * Pemetrexed/pembrolizumab * Pemetrexed * Nivolumab (single agent or in combination with other regimens in this list) * Ipilimumab/nivolumab * Carboplatin/etoposide * Carboplatin/etoposide/atezolizumab * Cisplatin/etoposide * Cisplatin/etoposide/atezolizumab * Durvalumab (single agent or in combination with other regimens in this list) * Atezolizumab (single agent or in combination with other regimens in this list) * Patients eligible for the systemic therapy regimens notes * Patients with Stage IV NSCLC who have symptomatic (defined by patient-reported cough, dyspnea, or hemoptysis) or near-symptomatic (determined radiographically to be threatening the airway, esophagus or vasculature) centrally located. * KPS ≥ 60 * Age ≥ 18 years. * Able to provide informed consent. * Patients at reproductive potential must agree to practice an effective contraceptive method. Exclusion Criteria: * Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that res…

What they're measuring

Dose Limiting Toxicity

Timeframe: 3 months

Trial details

NCT IDNCT04384146

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-05